We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Chiral Technologies Acquires Diffinity Genomics

Chiral Technologies Acquires Diffinity Genomics

Chiral Technologies Acquires Diffinity Genomics

Chiral Technologies Acquires Diffinity Genomics

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Chiral Technologies Acquires Diffinity Genomics"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Diffinity Genomics has developed novel technology for the purification of nucleic acids, which formed the foundation for their products in DNA purification markets. The Diffinity RapidTip®technology provides a method for rapid purification of amplified DNA fragments from Polymerase Chain Reaction (PCR) in a single step.

“The innovative, patented purification technology from Diffinity was a perfect choice for our expansion in the bio-separation/purification marketspace,” commented Joseph Barendt, Ph.D., COO of Chiral Technologies, Inc.

As a new business unit of Chiral Technologies, Diffinity’s product portfolio demonstrates Chiral Technologies’ commitment to providing the health sciences industry with innovative separation technologies and ensures our customers will have access to new opportunities in DNA purification.

Joseph Marasco, Ph.D., CEO of Diffinity Genomics, stated: “We are very pleased to become part of Chiral Technologies. We are confident that this is an ideal fit with Chiral Technologies as a multinational development partner to commercialize Diffinity’s unique technologies.”

Mike Riedlinger, one of Diffinity’s co-founders and board member, stated: “We’d like to express our thanks to Dr. Joseph Marasco for all of his contributions to the company since he joined in 2012. As CEO, Joe played a critical role in finding the right partner and then managing the acquisition and operation of the company to its successful outcome.”

Upon the successful completion of the acquisition, Dr. Marasco will leave Diffinity Genomics to pursue other interests.